Absence of polo-like kinase 3 in mice stabilizes Cdc25A after DNA damage but is not sufficient to produce tumors

Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis

Volumn 714, Issue 1-2, 2011, Pages 1-10

  Myer, David L ^a   Robbins, Susan B ^a   Yin, Moying ^a,b   Boivin, Gregory P ^b   Liu, Yang ^a   Greis, Kenneth D ^a   Bahassi, El Mustapha ^a   Stambrook, Peter J ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b WRIGHT STATE UNIVERSITY   (United States)

Author keywords

Cdc25A; Checkpoints; DNA damage; Polo like kinases; Ubiquitinylation

Indexed keywords

CYCLIN B; DOUBLE STRANDED DNA; ETOPOSIDE; POLO LIKE KINASE 3; PROTEIN PHOSPHATASE CDC25A; PROTEIN TYROSINE PHOSPHATASE; SERINE; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INCIDENCE; CANCER SUSCEPTIBILITY; CARBOXY TERMINAL SEQUENCE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE S PHASE; CONTROLLED STUDY; DNA DAMAGE; DNA STRAND BREAKAGE; FEMALE; HETEROZYGOSITY; HOMOZYGOSITY; KNOCKOUT MOUSE; MALE; MOUSE; MUTATION; NONHUMAN; POLYPLOIDY; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN STABILITY; SEX DIFFERENCE; THYMOCYTE; TUMOR VOLUME;

ANIMALS; CDC25 PHOSPHATASES; CELL CYCLE; CELL LINE; DNA DAMAGE; MICE; MICE, KNOCKOUT; NEOPLASMS; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; UBIQUITINATION;

MUS;

EID: 80051823334     PISSN: 00275107     EISSN: 09218262     Source Type: Journal    
DOI: 10.1016/j.mrfmmm.2011.02.006     Document Type: Article

References (58)

1. Glover D.M., Hagan I.M., Tavares A.A.M. Polo-like kinases: a team that plays throughout mitosis. Genes Dev. 1998, 12:3777-3787.
2. Barr F.A., Sillje H.H., Nigg E.A. Polo-like kinases and the orchestration of cell division. Nat. Rev. Mol. Cell Biol. 2004, 5:429-440.
3. Lane H.A., Nigg E.A. Antibody microinjection reveals an essential role for human polo-like kinase 1 (Plk1) in the functional maturation of mitotic centrosomes. J. Cell Biol. 1996, 135:1701-1713.
4. Qian Y.W., Erikson E., Li C., Maller J.L. Activated polo-like kinase Plx1 is required at multiple points during mitosis in Xenopus laevis. Mol. Cell. Biol. 1998, 18:4262-4271.
5. Moutinho-Santos T., Sampaio P., Amorim I., Costa M., Sunkel C.E. In vivo localisation of the mitotic POLO kinase shows a highly dynamic association with the mitotic apparatus during early embryogenesis in Drosophila. Biol. Cell 1999, 91:585-596.
6. Smits V.A., Klompmaker R., Arnaud L., Rijksen G., Nigg E.A., Medema R.H. Polo-like kinase-1 is a target of the DNA damage checkpoint. Nat. Cell Biol. 2000, 2:672-676.
7. Bahassi E.M., Conn C.W., Myer D.L., Hennigan R.F., McGowan C.H., Sanchez Y., Stambrook P.J. Mammalian Polo-like kinase 3 (Plk3) is a multifunctional protein involved in stress response pathways. Oncogene 2002, 21:6633-6640.
8. Xie S., Wu H., Wang Q., Kunicki J., Thomas R.O., Hollingsworth R.E., Cogswell J., Dai W. Genotoxic stress-induced activation of Plk3 is partly mediated by Chk2. Cell Cycle 2002, 1:424-429.
9. Llamazares S., Moreira A., Tavares A., Girdham C., Spruce B.A., Gonzalez C., Karess R.E., Glover D.M., Sunkel C.E. Polo encodes a protein kinase homolog required for mitosis in Drosophila. Genes Dev. 1991, 5:2153-2165.
10. Sunkel C.E., Glover D.M. Polo, a mitotic mutant of Drosophila displaying abnormal spindle poles. J. Cell Sci. 1988, 89:25-38.
11. Logarinho E., Sunkel C.E. The Drosophila POLO kinase localises to multiple compartments of the mitotic apparatus and is required for the phosphorylation of MPM2 reactive epitopes. J. Cell Sci. 1998, 111:2897-2909.
12. Song S., Grenfell T.Z., Garfield S., Erikson R.L., Lee K.S. Essential function of the polo box of Cdc5 in subcellular localization and induction of cytokinetic structures. Mol. Cell. Biol. 2000, 20:286-298.
13. Ohkura H., Hagan I.M., Glover D.M. The conserved Schizosaccharomyces pombe kinase plo1, required to form a bipolar spindle, the actin ring, and septum, can drive septum formation in G1 and G2 cells. Genes Dev. 1995, 9:1059-1073.
14. Lowery D.M., Lim D., Yaffe M.B. Structure and function of Polo-like kinases. Oncogene 2005, 24:248-259.
15. Andrysik Z., Bernstein W.Z., Deng L., Myer D.L., Li Y.Q., Tischfield J.A., Stambrook P.J., Bahassi E.M. The novel mouse Polo-like kinase 5 responds to DNA damage and localizes in the nucleolus. Nucleic Acids Res. 2010, 38:2931-2943.
16. Lee K.S., Grenfell T.Z., Yarm F.R., Erikson R.L. Mutation of the polo-box disrupts localization and mitotic functions of the mammalian polo kinase Plk. Proc. Natl. Acad. Sci. U.S.A. 1998, 95:9301-9306.
17. van de Weerdt B.C., Littler D.R., Klompmaker R., Huseinovic A., Fish A., Perrakis A., Medema R.H. Polo-box domains confer target specificity to the Polo-like kinase family. Biochim. Biophys. Acta 2008, 1783:1015-1022.
18. Elia A.E., Cantley L.C., Yaffe M.B. Proteomic screen finds pSer/pThr-binding domain localizing Plk1 to mitotic substrates. Science 2003, 299:1228-1231.
19. Elia A.E., Rellos P., Haire L.F., Chao J.W., Ivins F.J., Hoepker K., Mohammad D., Cantley L.C., Smerdon S.J., Yaffe M.B. The molecular basis for phosphodependent substrate targeting and regulation of Plks by the Polo-box domain. Cell 2003, 115:83-95.
20. Nigg E.A. Polo-like kinases: positive regulators of cell division from start to finish. Curr. Opin. Cell Biol. 1998, 10:776-783.
21. Carmena M., Riparbelli M.G., Minestrini G., Tavares A.M., Adams R., Callaini G., Glover D.M. Drosophila polo kinase is required for cytokinesis. J. Cell Biol. 1998, 143:659-671.
22. Lin C.Y., Madsen M.L., Yarm F.R., Jang Y.J., Liu X., Erikson R.L. Peripheral Golgi protein GRASP65 is a target of mitotic polo-like kinase (Plk) and Cdc2. Proc. Natl. Acad. Sci. U.S.A. 2000, 97:12589-12594.
23. Sutterlin C., Lin C.Y., Feng Y., Ferris D.K., Erikson R.L., Malhotra V. Polo-like kinase is required for the fragmentation of pericentriolar Golgi stacks during mitosis. Proc. Natl. Acad. Sci. U.S.A. 2001, 98:9128-9132.
24. Shirayama M., Zachariae W., Ciosk R., Nasmyth K. The Polo-like kinase Cdc5p and the WD-repeat protein Cdc20p/fizzy are regulators and substrates of the anaphase promoting complex in Saccharomyces cerevisiae. EMBO J. 1998, 17:1336-1349.
25. Zimmerman W.C., Erikson R.L. Polo-like kinase 3 is required for entry into S phase. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:1847-1852.
26. Ando K., Ozaki T., Yamamoto H., Furuya K., Hosoda M., Hayashi S., Fukuzawa M., Nakagawara A. Polo-like kinase 1 (Plk1) inhibits p53 function by physical interaction and phosphorylation. J. Biol. Chem. 2004, 279:25549-25561.
27. Xie S., Wu H., Wang Q., Cogswell J.P., Husain I., Conn C., Stambrook P., Jhanwar-Uniyal M., Dai W. Plk3 functionally links DNA damage to cell cycle arrest and apoptosis at least in part via the p53 pathway. J. Biol. Chem. 2001, 276:43305-43312.
28. Bahassi E.M., Myer D.L., McKenney R.J., Hennigan R.F., Stambrook P.J. Priming phosphorylation of Chk2 by polo-like kinase 3 (Plk3) mediates its full activation by ATM and a downstream checkpoint in response to DNA damage. Mutat. Res. 2006, 596:166-176.
29. Yang Y., Bai J., Shen R., Brown S.A., Komissarova E., Huang Y., Jiang N., Alberts G.F., Costa M., Lu L., Winkles J.A., Dai W. Polo-like kinase 3 functions as a tumor suppressor and is a negative regulator of hypoxia-inducible factor-1 alpha under hypoxic conditions. Cancer Res. 2008, 68:4077-4085.
30. Chehab N.H., Malikzay A., Appel M., Halazonetis T.D. Chk2/hCds1 functions as a DNA damage checkpoint in G(1) by stabilizing p53. Genes Dev. 2000, 14:278-288.
31. Bahassi E.M., Hennigan R.F., Myer D.L., Stambrook P.J. Cdc25C phosphorylation on serine 191 by Plk3 promotes its nuclear translocation. Oncogene 2004, 23:2658-2663.
32. Busino L., Donzelli M., Chiesa M., Guardavaccaro D., Ganoth D., Dorrello N.V., Hershko A., Pagano M., Draetta G.F. Degradation of Cdc25A by beta-TrCP during S phase and in response to DNA damage. Nature 2003, 426:87-91.
33. Falck J., Mailand N., Syljuasen R.G., Bartek J., Lukas J. The ATM-Chk2-Cdc25A checkpoint pathway guards against radioresistant DNA synthesis. Nature 2001, 410:842-847.
34. Bernardi R., Lieberman D.A., Hoffman B. Cdc25A stability is controlled by the ubiquitin-proteasome pathway during cell cycle progression and terminal differentiation. Oncogene 2000, 19:2447-2454.
35. Boutros R., Dozier C., Ducommun B. The when and whereas of CDC25 phosphatases. Curr. Opin. Cell Biol. 2006, 18:185-191.
36. Donzelli M., Squatrito M., Ganoth D., Hershko A., Pagano M., Draetta G.F. Dual mode of degradation of Cdc25 A phosphatase. EMBO J. 2002, 21:4875-4884.
37. Busino L., Chiesa M., Draetta G.F., Donzelli M. Cdc25A phosphatase: combinatorial phosphorylation, ubiquitylation and proteolysis. Oncogene 2004, 23:2050-2056.
38. Chen M.S, Ryan C.E., Piwnica-Worms H. Chk1 kinase negatively regulates mitotic function of Cdc25A phosphatase through 14-3-3 binding. Mol. Cell. Biol. 2003, 23:7488-7497.
39. Mailand N., Falck J., Lukas C., Syljuasen R.G., Welcker M., Bartek J., Lukas J. Rapid destruction of human Cdc25A in response to DNA damage. Science 2000, 288:1425-1429.
40. Molinari M., Mercurio C., Dominguez J., Goubin F., Draetta G.F. Human Cdc25A inactivation in response to S phase inhibition and its role in preventing premature mitosis. EMBO Rep. 2000, 1:71-79.
41. Blomberg I., Hoffmann I. Ectopic expression of Cdc25A accelerates the G(1)/S transition and leads to premature activation of cyclin E- and cyclin A-dependent kinases. Mol. Cell. Biol. 1999, 19:6183-6194.
42. Bartek J., Lukas J. Pathways governing G1/S transition and their response to DNA damage. FEBS Lett. 2001, 490:117-122.
43. Zhao H., Watkins J.L., Piwnica-Worms H. Disruption of the checkpoint kinase 1/cell division cycle 25A pathway abrogates ionizing radiation-induced S and G2 checkpoints. Proc. Natl. Acad. Sci. U.S.A. 2002, 99:14795-14800.
44. Kristjansdottir K., Rudolph J. CDC25 phosphatases and cancer. Chem. Biol. 2004, 11:1043-1051.
45. Kang T., Wei Y., Honaker Y., Yamaguchi H., Appella E., Hung M.C., Piwnica-Worms H. GSK-3 beta targets Cdc25A for ubiquitin-mediated proteolysis, and GSK-3 beta inactivation correlates with Cdc25A overproduction in human cancers. Cancer Cell 2008, 13:36-47.
46. Melixetian M., Klein D.K., Sørensen C.S., Helin K. NEK11 regulates CDC25A degradation and the IR-induced G2/M checkpoint. Nat. Cell Biol. 2009, 11:1247-1253.
47. Isoda M., Kanemori Y., Nakajo N., Uchida S., Yamashita K., Ueno H., Sagata N. The extracellular signal-regulated kinase-mitogen-activated protein kinase pathway phosphorylates and targets Cdc25A for SCF beta-TrCP-dependent degradation for cell cycle arrest. Mol. Biol. Cell 2009, 20:2186-2195.
48. Ray D., Terao Y., Nimbalkar D., Chu L.H., Donzelli M., Tsutsui T., Zou X., Ghosh A.K., Varga J., Draetta G.F., Kiyokawa H. Transforming growth factor beta facilitates beta-TrCP-mediated degradation of Cdc25A in a Smad3-dependent manner. Mol. Cell. Biol. 2005, 25:3338-3347.
49. Eismann T., Huber N., Shin T., Kuboki S., Galloway E., Wyder M., Edwards M.J., Greis K.D., Shertzer H.G., Fisher A.B., Lensch A.B. Peroxiredoxin-6 protects against mitochondrial dysfunction and liver injury during ischemia-reperfusion in mice. Am. J. Physiol. Gastrointest. Liver Physiol. 2009, 296:G266-G274.
50. Thingholm T.E., Jensen O.N., Robinson P.J., Larsen M.R. SIMAC (sequential elution from IMAC), a phosphoproteomics strategy for the rapid separation of monophosphorylated from multiply phosphorylated peptides. Cell Proteomics 2008, 7:661-671.
51. Dai W., Cogswell J.P. Polo-like kinases and the microtubule organization center: targets for cancer therapies. Prog. Cell Cycle Res. 2003, 5:327-334.
52. Honaker Y., Piwnica-Worms H. Casein kinase 1 functions as both penultimate and ultimate kinase in regulating Cdc25A destruction. Oncogene 2010, 29:3324-3334.
53. Jin J., Shirogane T., Xu L., Nalepa G., Qin J., Elledge S.J., Harper J.W. SCFbeta-TRCP links Chk1 signaling to degradation of the Cdc25A protein phosphatase. Genes Dev. 2003, 17:3062-3074.
54. Goloudina A., Yamaguchi H., Chervyakova D.B., Appella E., Fornace A.J., Bulavin D.V. Regulation of human Cdc25A stability by Serine 75 phosphorylation is not sufficient to activate a S phase checkpoint. Cell Cycle 2003, 2:473-478.
55. Boutros R., Lobjois V., Ducommun B. CDC25 phosphatases in cancer cells: Key players? Good targets?. Nat. Rev. Cancer 2007, 7:495-507.
56. Halazonetis T.D., Gorgoulis V.G., Bartek J. An oncogene-induced DNA damage model for cancer development. Science 2008, 319:1352-1355.
57. Fox J.G., Feng Y., Theve E.J., Raczynski A.R., Fiala J.L.A., Doernte A.L., Williams M., et al. Gut microbes define liver cancer risk in mice exposed to chemical and viral transgenic hepatocarcinogens. Gut 2010, 59:88-97.
58. Ivanov I.I., Atarashi K., Manel N., Brodie E.L., Shima T., Karaoz U., Wei D., et al. Induction of intestinal Th17 cells by segmented filamentous bacteria. Cell 2009, 139:485-498.